

# Liona C Poon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4284249/publications.pdf>

Version: 2024-02-01

257  
papers

17,539  
citations

15504

65  
h-index

17105

122  
g-index

274  
all docs

274  
docs citations

274  
times ranked

11277  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of embryo morphology following perinatal exposure to aspirin, ibuprofen and paracetamol using whole embryo culture system. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2024, 35, 8786-8793.	1.5	2
2	First trimester preeclampsia screening and prediction. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1071-S1097.e2.	1.3	135
3	Prevention of preeclampsia with aspirin. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, S1108-S1119.	1.3	140
4	Prelabor short-term variability in fetal heart rate by computerized cardiotocogram and maternal fetal doppler indices for the prediction of labor outcomes. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 1318-1327.	1.5	6
5	The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. <i>Pregnancy Hypertension</i> , 2022, 27, 148-169.	1.4	189
6	Prospective Evaluation of International Prediction of Pregnancy Complications Collaborative Network Models for Prediction of Preeclampsia: Role of Serum sFlt-1 at 11â€“13 Weeksâ€™ Gestation. <i>Hypertension</i> , 2022, 79, 314-322.	2.7	4
7	Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed <sc>SARSâ€™CoV</sc>â€™2 infection: analysis of 13â€™062 positive pregnancies including 176 maternal deaths in Mexico. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 76-82.	1.7	17
8	The diagnosis and management of suspected fetal growth restriction: an evidence-based approach. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 366-378.	1.3	51
9	Effects of strict public health measures on seroprevalence of antiâ€™SARS-CoV-2 antibodies during pregnancy. , 2022, , .		0
10	Screening for spontaneous preterm birth by cervical length and shear-wave elastography in the first trimester of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 500.e1-500.e14.	1.3	7
11	Prediction of spontaneous preterm birth and preterm prelabor rupture of membranes using maternal factors, obstetric history and biomarkers of placental function at 11â€™13â€™weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 192-199.	1.7	10
12	Impact of replacing or adding pregnancyâ€™associated plasma <sc>proteinâ€™A</sc> at 11â€™13â€™weeks on screening for preterm preâ€™eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 200-206.	1.7	6
13	<sc>SARSâ€™CoV</sc>â€™2â€™specific antibodies and neutralization capacity in breast milk following infection <i>vs</i> vaccination. <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 60, 425-427.	1.7	3
14	First Trimester Screening for Gestational Diabetes Mellitus with Maternal Factors and Biomarkers. <i>Fetal Diagnosis and Therapy</i> , 2022, 49, 256-264.	1.4	6
15	Outcome of radiofrequency ablation for selective fetal reduction before <i>vs</i> at or after 16â€™gestational weeks in complicated monochorionic pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 214-220.	1.7	12
16	Incidence of preâ€™eclampsia and other perinatal complications among pregnant women with congenital heart disease: systematic review and metaâ€™analysis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 519-528.	1.7	7
17	Dopplerâ€™based predictive model for methotrexate resistance in lowâ€™risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 829-839.	1.7	2
18	Accuracy of the FMF Bayes theorem-based model for predicting preeclampsia at 11â€™13 weeks of gestation in a Japanese population. <i>Hypertension Research</i> , 2021, 44, 685-691.	2.7	8

#	ARTICLE	IF	CITATIONS
19	Pregnant women with <sc>SARSâ€CoV</sc>â€2 infection are at higher risk of death and pneumonia: propensity score matched analysis of a nationwide prospective cohort (<sc>COV19Mx</sc>). <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 224-231.	1.7	126
20	Comparison of uterine artery Doppler measurements at 6Âweeks of pregnancy after IVF between pregnancies that resulted in miscarriage and ongoing pregnancies. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 249-255.	2.3	3
21	Bradycardiaâ€toâ€delivery interval and fetal outcomes in umbilical cord prolapse. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 170-177.	2.8	17
22	Singleâ€cell <sc>RNA</sc> expression profiling of SARSâ€CoVâ€2â€related <sc>ACE2</sc> and <sc>TMPRSS2</sc> in human trophoctoderm and placenta. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 248-256.	1.7	54
23	The Use of Somatex Shunt for Fetal Pleural Effusion: A Cohort of 8 Procedures. <i>Fetal Diagnosis and Therapy</i> , 2021, 48, 440-447.	1.4	3
24	How has COVID-19 impacted obstetrics?. , 2021, 21, 9-11.		1
25	Scientific effort in combating COVID â€19 in obstetrics and gynecology. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 189-194.	1.7	2
26	FIGO (International Federation of Gynecology and Obstetrics) initiative on fetal growth: Best practice advice for screening, diagnosis, and management of fetal growth restriction. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 3-57.	2.3	188
27	First Trimester Screening for Preeclampsia: An Asian Perspective. <i>Maternal-Fetal Medicine</i> , 2021, 3, 116-123.	0.8	2
28	The significance of low first trimester serum progesterone in ongoing early pregnancies presenting as pregnancies of unknown location. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 258, 294-298.	1.1	0
29	Prediction of spontaneous preterm birth by cervical length in the first trimester of pregnancy: Comparison of two measurement methods. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1305-1312.	2.8	7
30	How Different Are Diverse Populations in Screening for Preeclampsia?. <i>Maternal-Fetal Medicine</i> , 2021, 3, 87-90.	0.8	0
31	Preeclampsia: Universal Screening or Universal Prevention for Low and Middle-Income Settings?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021, 43, 334-338.	0.8	4
32	Young pregnant women are also at an increased risk of mortality and severe illness due to coronavirus disease 2019: analysis of the Mexican National Surveillance Program. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 404-407.	1.3	16
33	Impact of replacing or adding placental growth factor on Down syndrome screening: A prospective cohort study. <i>Prenatal Diagnosis</i> , 2021, 41, 1111-1117.	2.3	2
34	Update on diagnosis of hyperglycemia in pregnancy and gestational diabetes mellitus from FIGOâ€™s Pregnancy & Nonâ€Communicable Diseases Committee. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 154, 189-194.	2.3	7
35	Relationship between viral load, infectionâ€toâ€delivery interval and motherâ€toâ€child transfer of <sc>antiâ€SARSâ€CoV</sc>â€2 antibodies. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 57, 974-978.	1.7	16
36	The usefulness of ultrasound before induction of labor. <i>American Journal of Obstetrics &amp; Gynecology MFM</i> , 2021, 3, 100423.	2.6	6

#	ARTICLE	IF	CITATIONS
37	A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 154, 3-31.	2.3	34
38	Effective Aspirin Treatment of Women at Risk for Preeclampsia Delays the Metabolic Clock of Gestation. <i>Hypertension</i> , 2021, 78, 1398-1410.	2.7	10
39	Application of an individualized nomogram in first-trimester screening for trisomy 21. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 56-66.	1.7	12
40	Cost-utility of a first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. <i>Pregnancy Hypertension</i> , 2021, 25, 219-224.	1.4	12
41	Novel Ratio Soluble Fms-like Tyrosine Kinase-1/Angiotensin-II (sFlt-1/ANG-II) in Pregnant Women Is Associated with Critical Illness in COVID-19. <i>Viruses</i> , 2021, 13, 1906.	3.3	23
42	Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low- and middle-income countries. <i>AJOG Global Reports</i> , 2021, 1, 100020.	1.0	6
43	Evidence of possible SARS-CoV-2 vertical transmission according to World Health Organization criteria in asymptomatic pregnant women. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 900-908.	1.7	16
44	ASPREE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 546-552.	1.7	8
45	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, 58, 643-644.	1.7	0
46	Increased levels of soluble fms-like tyrosine kinase-1 are associated with adverse outcomes in pregnant women with COVID-19. <i>Ultrasound in Obstetrics and Gynecology</i> , 2021, , .	1.7	13
47	The use of ultrasound, fibronectin and other parameters to predict the success of labour induction. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 79, 27-27.	2.8	1
48	Single-molecule sequencing reveals a large population of long cell-free DNA molecules in maternal plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	43
49	Does low-dose aspirin initiated before 11 weeks gestation reduce the rate of preeclampsia?. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 437-450.	1.3	40
50	From first-trimester screening to risk stratification of evolving pre-eclampsia in second and third trimesters of pregnancy: comprehensive approach. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 5-12.	1.7	24
51	The predictive value of cervical shear wave elastography in the outcome of labor induction. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 59-68.	2.8	25
52	First-trimester pre-eclampsia biomarker profiles in Asian population: multicenter cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 206-214.	1.7	25
53	Effect of race on longitudinal central hemodynamics in pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 37-43.	1.7	2
54	Feasibility, Reliability, and Agreement of Transperineal Ultrasound Measurement: Results from a Longitudinal Cohort Study. <i>Fetal Diagnosis and Therapy</i> , 2020, 47, 721-730.	1.4	3

#	ARTICLE	IF	CITATIONS
55	ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 298-312.	1.7	351
56	Risk factors for anxiety and depression among pregnant women during the COVID-19 pandemic. <i>Medicine (United States)</i> , 2020, 99, e21279.	1.0	69
57	Detection and characterization of jagged ends of double-stranded DNA in plasma. <i>Genome Research</i> , 2020, 30, 1144-1153.	5.5	61
58	Bronchopulmonary sequestration successfully treated with prenatal radiofrequency ablation of the feeding artery. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 58, 325-327.	1.7	0
59	Transperineal ultrasound assessment of fetal head elevation by maneuvers used for managing umbilical cord prolapse. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 58, 603-608.	1.7	4
60	Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 56, 15-27.	1.7	424
61	Plasma DNA End-Motif Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. <i>Cancer Discovery</i> , 2020, 10, 664-673.	9.4	152
62	<sc>ISUOG</sc> Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 700-708.	1.7	179
63	Maternal cardiac function in women at high risk for pre-eclampsia treated with 150mg aspirin or placebo: an observational study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1018-1025.	2.3	10
64	ISUOG Safety Committee Position Statement on safe performance of obstetric and gynecological scans and equipment cleaning in context of COVID-19. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 709-712.	1.7	39
65	Novel coronavirus infection and pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 435-437.	1.7	127
66	Whole genome miRNA profiling revealed miR-199a as potential placental pathogenesis of selective fetal growth restriction in monochorionic twin pregnancies. <i>Placenta</i> , 2020, 92, 44-53.	1.5	18
67	Shear-wave sonoelastographic assessment of cervix in pregnancy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1458-1468.	2.8	6
68	<sc>ISUOG</sc> Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals – an update. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 848-862.	1.7	80
69	Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 149, 273-286.	2.3	220
70	ISUOG Consensus Statement on organization of routine and specialist obstetric ultrasound services in context of COVID-19. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 863-870.	1.7	38
71	ISUOG Safety Committee Position Statement on use of personal protective equipment and hazard mitigation in relation to SARS-CoV-2 for practitioners undertaking obstetric and gynecological ultrasound. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 886-891.	1.7	35
72	Intrauterine vertical transmission of SARS-CoV-2: what we know so far. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 724-725.	1.7	62

#	ARTICLE	IF	CITATIONS
73	Placental microRNA dataset of monochorionic twin pregnancies with and without selective fetal growth restriction. <i>Data in Brief</i> , 2020, 30, 105403.	1.0	2
74	Coronavirus disease 2019 in pregnant women: a report based on 116 cases. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 111.e1-111.e14.	1.3	489
75	Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic. <i>Ultrasound in Obstetrics and Gynecology</i> , 2020, 55, 841-843.	1.7	25
76	Mini-combined test compared with NICE guidelines for early risk-assessment for pre-eclampsia: the SPREE diagnostic accuracy study. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-156.	0.7	5
77	Monochorionic twins with selective fetal growth restriction: insight from placental whole-transcriptome analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 749.e1-749.e16.	1.3	3
78	Does Low-Dose Aspirin Initiated Before 11 Weeks™ Gestation Reduce the Rate of Preeclampsia?. <i>Obstetrical and Gynecological Survey</i> , 2020, 75, 581-582.	0.4	0
79	Pre-Induction Transperineal Ultrasound Assessment for the Prediction of Labor Outcome. <i>Fetal Diagnosis and Therapy</i> , 2019, 45, 256-267.	1.4	18
80	Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor. <i>Pregnancy Hypertension</i> , 2019, 17, 165-171.	1.4	17
81	Reasons for accepting or declining participation in the ASPRE trial: A qualitative study with women at high risk of preterm pre-eclampsia. <i>Prenatal Diagnosis</i> , 2019, 39, 1127-1135.	2.3	7
82	Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 650.e1-650.e16.	1.3	73
83	<scp>FIGO</scp> (International Federation of Gynecology and Obstetrics) Postpregnancy Initiative: Long-term Maternal Implications of Pregnancy Complications—Follow-up Considerations. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 147, 1-31.	2.3	50
84	Labor progress determined by ultrasound is different in women requiring cesarean delivery from those who experience a vaginal delivery following induction of labor. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 335.e1-335.e18.	1.3	28
85	Clinical evaluation of a first trimester pregnancy algorithm predicting the risk of small for gestational age neonates. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2019, 59, 670-676.	1.0	3
86	Good clinical practice advice: Iron deficiency anemia in pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 144, 322-324.	2.3	28
87	Good clinical practice advice: Management of twin pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 144, 330-337.	2.3	32
88	Predictive performance of the competing risk model in screening for preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 199.e1-199.e13.	1.3	136
89	Good clinical practice advice: Micronutrients in the periconceptual period and pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 144, 317-321.	2.3	9
90	Good clinical practice advice: First trimester screening and prevention of pre-eclampsia in singleton pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 144, 325-329.	2.3	13

#	ARTICLE	IF	CITATIONS
91	Good clinical practice advice: Role of ultrasound in the management of twin pregnancy. International Journal of Gynecology and Obstetrics, 2019, 144, 338-339.	2.3	8
92	Good clinical practice advice: Prediction of preterm labor and preterm premature rupture of membranes. International Journal of Gynecology and Obstetrics, 2019, 144, 340-346.	2.3	23
93	Good clinical practice advice: Thyroid and pregnancy. International Journal of Gynecology and Obstetrics, 2019, 144, 347-351.	2.3	10
94	Good clinical practice advice: Antenatal corticosteroids for fetal lung maturation. International Journal of Gynecology and Obstetrics, 2019, 144, 352-355.	2.3	29
95	The International Federation of Gynecology and Obstetrics (<scp>FIGO</scp>) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. International Journal of Gynecology and Obstetrics, 2019, 145, 1-33.	2.3	550
96	The effect of parity on longitudinal maternal hemodynamics. American Journal of Obstetrics and Gynecology, 2019, 221, 249.e1-249.e14.	1.3	18
97	Factors that affect ultrasound-determined labor progress in women undergoing induction of labor. American Journal of Obstetrics and Gynecology, 2019, 220, 592.e1-592.e15.	1.3	16
98	Genetic association of retroesophageal left brachiocephalic vein. Ultrasound in Obstetrics and Gynecology, 2019, 54, 836-837.	1.7	3
99	Do specific ultrasonography features identified at the time of early pregnancy loss predict fetal chromosomal abnormality? â€“ A systematic review and meta-analysis. Genes and Diseases, 2019, 6, 129-137.	3.4	2
100	Prenatal visualization of paraumbilical veins in fetus with intra-abdominal umbilical vein stricture and intrauterine growth restriction. Ultrasound in Obstetrics and Gynecology, 2019, 54, 697-698.	1.7	0
101	Screening and Prevention of Preeclampsia. Maternal-Fetal Medicine, 2019, 1, 25-30.	0.8	16
102	Impact of preimplantation genetic testing for aneuploidy on obstetrical practice. Current Opinion in Obstetrics and Gynecology, 2019, 31, 127-131.	2.0	2
103	Reproductive outcomes after surgical treatment of asherman syndrome: A systematic review. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2019, 59, 98-114.	2.8	46
104	Objective assessment of the fetal facial profile at second and third trimester of pregnancy. Prenatal Diagnosis, 2019, 39, 107-115.	2.3	16
105	Transvaginal three-dimensional ultrasound assessment of Sylvian fissures at 18-30 weeks' gestation. Ultrasound in Obstetrics and Gynecology, 2019, 54, 190-198.	1.7	28
106	Increased Sylvian fissure angle as early sonographic sign of malformation of cortical development. Ultrasound in Obstetrics and Gynecology, 2019, 54, 199-206.	1.7	29
107	Maternal hemodynamics in screen-positive and screen-negative women of the ASPRE trial. Ultrasound in Obstetrics and Gynecology, 2019, 54, 51-57.	1.7	17
108	Prediction of labor outcome using serial transperineal ultrasound in the first stage of labor. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 31-37.	1.5	18

#	ARTICLE	IF	CITATIONS
109	Body mass index at 11â€“13 weeksâ€™ gestation and pregnancy complications in a Southern Chinese population: a retrospective cohort study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 2056-2068.	1.5	14
110	Maternal hemodynamics, fetal biometry and Doppler indices in pregnancies followed up for suspected fetal growth restriction. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 507-514.	1.7	40
111	Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 743-750.	1.7	219
112	ASPREE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 738-742.	1.7	54
113	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 464-465.	1.3	0
114	Aspirin Versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 11-12.	0.4	5
115	Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 93-102.	5.6	146
116	Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPREE. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 52-59.	1.7	91
117	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 612.e1-612.e6.	1.3	84
118	Effect of change in posture on maternal functional hemodynamics at 35â€“37 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 368-374.	1.7	9
119	Uterine artery pulsatility index in the first trimester: assessment of intersonographer and intersampling site measurement differences. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 2276-2283.	1.5	14
120	Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age. <i>Fetal Diagnosis and Therapy</i> , 2018, 43, 250-265.	1.4	16
121	Transverse technique: complementary approach to measurement of first-trimester uterine artery Doppler. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 639-647.	1.7	11
122	ASPREE Trial: Incidence of Preterm Preeclampsia in Patients Fulfilling ACOG and NICE Criteria According to Risk by FMF Algorithm. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 623-625.	0.4	0
123	Comment on "First Trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors". <i>Prenatal Diagnosis</i> , 2018, 38, 891-891.	2.3	0
124	The first-trimester of pregnancy "A window of opportunity for prediction and prevention of pregnancy complications and future life. <i>Diabetes Research and Clinical Practice</i> , 2018, 145, 20-30.	2.8	71
125	Screening for pre-eclampsia by maternal factors and biomarkers at 11â€“13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 52, 186-195.	1.7	241
126	Accuracy of competing risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11â€“13 weeks' gestation. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 751-755.	1.7	182



#	ARTICLE	IF	CITATIONS
127	Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 756-760.	1.7	251
128	Re: Impact of aspirin on trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks: a randomized controlled study. E. Scazzocchio, D. Oros, D. Diaz, J. C. Ramirez, M. Ricart, E. Meler, R. González de Agüero, E. Gratacos and F. Fi. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 433-433.	1.7	1
129	Protocol for the prospective validation study: "Screening programme for pre-eclampsia" (SPREE). <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 175-179.	1.7	11
130	Integrative single-cell and cell-free plasma RNA transcriptomics elucidates placental cellular dynamics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7786-E7795.	7.1	242
131	Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 685.e1-685.e5.	1.3	100
132	ASPRE trial: performance of screening for preterm pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 50, 492-495.	1.7	263
133	Protocol for measurement of mean arterial pressure at 10-40 weeks' gestation. <i>Pregnancy Hypertension</i> , 2017, 10, 155-160.	1.4	23
134	Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 585.e1-585.e5.	1.3	136
135	Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. <i>New England Journal of Medicine</i> , 2017, 377, 613-622.	27.0	1,462
136	Metabolomic determination of pathogenesis of late-onset preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 658-664.	1.5	35
137	Maternal cardiovascular function at 35-37 weeks' gestation: relation to maternal characteristics. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 39-45.	1.7	15
138	Maternal cardiac function at 35-37 weeks' gestation: relationship with birth weight. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 67-72.	1.7	17
139	Maternal cardiac function at 35-37 weeks' gestation: prediction of pre-eclampsia and gestational hypertension. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 61-66.	1.7	20
140	Integrated Proteomic and Metabolomic prediction of Term Preeclampsia. <i>Scientific Reports</i> , 2017, 7, 16189.	3.3	33
141	STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. <i>BMC Pregnancy and Childbirth</i> , 2017, 17, 440.	2.4	43
142	Reply. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 789-789.	1.7	0
143	The effect of gestational age and cervical length measurements in the prediction of spontaneous preterm birth in twin pregnancies: an individual patient level meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 877-884.	2.3	54
144	First trimester prediction of HELLP syndrome. <i>Prenatal Diagnosis</i> , 2016, 36, 29-33.	2.3	11

#	ARTICLE	IF	CITATIONS
145	IONA test for first-trimester detection of trisomies 21, 18 and 13. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 184-187.	1.7	10
146	Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 332-339.	1.7	40
147	Cervical cerclage for preterm birth prevention in twin gestation with short cervix: a retrospective cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 752-756.	1.7	42
148	Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PReeclampsia prevention (ASPRE). <i>BMJ Open</i> , 2016, 6, e011801.	1.9	62
149	Birth weight in live births and stillbirths. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 48, 602-606.	1.7	106
150	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 392-393.	0.4	2
151	Clinical implementation of routine screening for fetal trisomies in the <sc>UK</sc> <sc>NHS</sc>: cell-free <sc>DNA</sc> test contingent on results from first-trimester combined test. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 45-52.	1.7	108
152	Clinical Implementation of Routine Screening for Fetal Trisomies in the UK NHS. <i>Obstetrical and Gynecological Survey</i> , 2016, 71, 275-276.	0.4	0
153	Risk of preterm birth following surgical treatment for cervical disease: executive summary of a recent symposium. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 1426-1429.	2.3	44
154	A Randomized Trial of a Cervical Pessary to Prevent Preterm Singleton Birth. <i>New England Journal of Medicine</i> , 2016, 374, 1044-1052.	27.0	156
155	Current controversies in prenatal diagnosis 3: is there still a value in a nuchal translucency screening ultrasound in conjunction with maternal plasma non-invasive cell-free DNA testing?. <i>Prenatal Diagnosis</i> , 2016, 36, 20-24.	2.3	6
156	The Use of Ultrasound and other Markers for Early Detection of Preeclampsia. <i>Women's Health</i> , 2016, 12, 199-207.	1.5	24
157	Cervical pessary placement for prevention of preterm birth in unselected twin pregnancies: a randomized controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 3.e1-3.e9.	1.3	120
158	Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 103.e1-103.e12.	1.3	365
159	Fetal fraction of cell-free <sc>DNA</sc> in maternal plasma in the prediction of spontaneous preterm delivery. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 101-105.	1.7	34
160	Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 698-706.	1.7	83
161	Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 35-37 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 715-721.	1.7	41
162	Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 332-340.	1.7	21

#	ARTICLE	IF	CITATIONS
163	Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 437-445.	1.7	53
164	Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 341-349.	1.7	37
165	Re: Prediction of early and late onset pregnancy induced hypertension using placental volume on three-dimensional ultrasound and uterine artery Doppler. T. Arakaki, J. Hasegawa, M. Nakamura, S. Hamada, M. Muramoto, H. Takita, K. Ichizuka and A. Sekizawa. <i>Ultrasound Obstet Gynecol</i> 2015; 45: 539-543. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 513-513.	1.7	2
166	Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 446-451.	1.7	39
167	Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 208-215.	1.7	21
168	Maternal Plasma Cell-Free DNA in the Prediction of Pre-Eclampsia. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 377-378.	0.4	2
169	Umbilical and fetal middle cerebral artery Doppler at 30-34 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 409-420.	1.7	61
170	Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 191-197.	1.7	25
171	Prediction of small-for-gestational-age neonates: screening by fetal biometry at 30-34 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 551-558.	1.7	60
172	Maternal serum anti-Müllerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 865-868.	1.5	15
173	Demographic factors that can be used to predict early-onset pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 535-539.	1.5	5
174	Competing risks model in screening for preeclampsia by maternal characteristics and medical history. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 62.e1-62.e10.	1.3	280
175	Prediction of small-for-gestational-age neonates: screening by uterine artery Doppler and mean arterial pressure at 30-34 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 707-714.	1.7	25
176	Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35-37 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 559-565.	1.7	52
177	Prediction of small-for-gestational-age neonates: screening by fetal biometry at 19-24 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 198-207.	1.7	28
178	Umbilical and fetal middle cerebral artery Doppler at 35-37 weeks' gestation in the prediction of adverse perinatal outcome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 46, 82-92.	1.7	85
179	UK NHS pilot study on cell-free DNA testing in screening for fetal trisomies: factors affecting uptake. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 67-73.	1.7	36
180	Maternal plasma cell-free DNA in the prediction of pre-eclampsia. <i>Ultrasound in Obstetrics and Gynecology</i> , 2015, 45, 106-111.	1.7	45

#	ARTICLE	IF	CITATIONS
181	Management of hypertriglyceridaemia-induced acute pancreatitis in pregnancy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 954-958.	1.5	7
182	Competing Risk Model in Screening for Preeclampsia by Mean Arterial Pressure and Uterine Artery Pulsatility Index at 30-33 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2014, 36, 18-27.	1.4	23
183	Maternal Serum Placental Growth Factor Isoforms 1 and 2 at 11-13, 20-24 and 30-34 Weeks' Gestation in Late-Onset Pre-Eclampsia and Small for Gestational Age Neonates. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 249-257.	1.4	14
184	Early Prediction of Preeclampsia. <i>Obstetrics and Gynecology International</i> , 2014, 2014, 1-11.	1.3	187
185	Is high fetal nuchal translucency associated with submicroscopic chromosomal abnormalities on array <scp>CGH</scp>?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 620-624.	1.7	49
186	First-Trimester Contingent Screening for Trisomies 21, 18, and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing. <i>Obstetrical and Gynecological Survey</i> , 2014, 69, 529-531.	0.4	0
187	Prediction of Preeclampsia by Mean Arterial Pressure at 11-13 and 20-24 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2014, 36, 28-37.	1.4	38
188	Competing Risks Model in Screening for Preeclampsia by Biophysical and Biochemical Markers at 30-33 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2014, 36, 9-17.	1.4	32
189	Optimal Method and Timing of Intrauterine Intervention in Twin Reversed Arterial Perfusion Sequence: Case Study and Meta-Analysis. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 267-279.	1.4	61
190	Maternal Serum Placental Growth Factor (PIGF) Isoforms 1 and 2 at 11-13 Weeks' Gestation in Normal and Pathological Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2014, 36, 106-116.	1.4	29
191	Competing Risks Model in Screening for Preeclampsia by Serum Placental Growth Factor and Soluble fms-Like Tyrosine Kinase-1 at 30-33 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 240-248.	1.4	56
192	Successful induction of labor: prediction by preinduction cervical length, angle of progression and cervical elastography. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 44, 468-475.	1.7	74
193	First-trimester maternal factors and biomarker screening for preeclampsia. <i>Prenatal Diagnosis</i> , 2014, 34, 618-627.	2.3	113
194	First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing. <i>Fetal Diagnosis and Therapy</i> , 2014, 35, 185-192.	1.4	51
195	How feasible is expectant management of interstitial ectopic pregnancy?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 317-321.	1.7	30
196	Association of placental perfusion, as assessed by magnetic resonance imaging and uterine artery Doppler ultrasound, and its relationship to pregnancy outcome. <i>Placenta</i> , 2013, 34, 885-891.	1.5	86
197	Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2013, 53, 532-539.	1.0	126
198	Maternal Serum Soluble Endoglin at 30-33 Weeks in the Prediction of Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 149-155.	1.4	15

#	ARTICLE	IF	CITATIONS
199	Fetal fraction in maternal plasma cell-free <sc>DNA</sc> at 11–13 weeks' gestation: relation to maternal and fetal characteristics. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 26-32.	1.7	325
200	Maternal serum retinol-binding protein-4 at 11–13 weeks' gestation in normal and pathological pregnancies. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 814-819.	3.4	35
201	Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free $\beta$ -Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 164-172.	1.4	32
202	Maternal serum cytokines at 30–33 weeks in the prediction of preeclampsia. <i>Prenatal Diagnosis</i> , 2013, 33, 823-830.	2.3	19
203	Association of placental T2 relaxation times and uterine artery Doppler ultrasound measures of placental blood flow. <i>Placenta</i> , 2013, 34, 474-479.	1.5	52
204	Systolic, Diastolic and Mean Arterial Pressure at 30-33 Weeks in the Prediction of Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 173-181.	1.4	26
205	Uterine Artery Doppler at 30-33 Weeks' Gestation in the Prediction of Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 156-163.	1.4	37
206	Meta-analysis of second-trimester markers for trisomy 21. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 41, 247-261.	1.7	220
207	Competing Risks Model in Early Screening for Preeclampsia by Biophysical and Biochemical Markers. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 8-15.	1.4	464
208	Combined Screening for Preeclampsia and Small for Gestational Age at 11–13 Weeks. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 16-27.	1.4	180
209	Second-Trimester Uterine Artery Doppler in the Prediction of Stillbirths. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 28-35.	1.4	43
210	Prediction of Preeclampsia by Uterine Artery Doppler at 20-24 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2013, 34, 241-247.	1.4	31
211	First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free <sc>DNA</sc> testing. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 41-50.	1.7	107
212	Second-Trimester Screening for Trisomy-21 Using Prefrontal Space Ratio. <i>Fetal Diagnosis and Therapy</i> , 2013, 34, 50-55.	1.4	9
213	Maternal Plasma Cell-Free Fetal and Maternal DNA at 11-13 Weeks' Gestation: Relation to Fetal and Maternal Characteristics and Pregnancy Outcomes. <i>Fetal Diagnosis and Therapy</i> , 2013, 33, 215-223.	1.4	179
214	Trichorionic and Dichorionic Triplet Pregnancies at 10-14 Weeks: Outcome after Embryo Reduction Compared to Expectant Management. <i>Fetal Diagnosis and Therapy</i> , 2013, 34, 199-205.	1.4	59
215	Maternal serum tumour necrosis factor receptor 1 (TNF-R1) at 30–33 weeks in the prediction of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 763-767.	1.5	3
216	Maternal serum activin-A at 30–33 weeks in the prediction of preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 733-737.	1.5	10

#	ARTICLE	IF	CITATIONS
217	Maternal Thyroid Function at Gestational Weeks 11â€“13 in Twin Pregnancies. <i>Thyroid</i> , 2013, 23, 1165-1171.	4.5	15
218	Protocol for Measurement of Mean Arterial Pressure at 11-13 Weeks' Gestation. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 42-48.	1.4	197
219	A Competing Risks Model in Early Screening for Preeclampsia. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 171-178.	1.4	182
220	C-reactive protein at 11â€“13 weeksâ€™ gestation in spontaneous early preterm delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 2475-2478.	1.5	9
221	First-Trimester Screening for Neural Tube Defects Using Alpha-Fetoprotein. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 109-114.	1.4	38
222	Birthweight with Gestation and Maternal Characteristics in Live Births and Stillbirths. <i>Fetal Diagnosis and Therapy</i> , 2012, 32, 156-165.	1.4	111
223	First-Trimester Screening for Spontaneous Preterm Delivery with Maternal Characteristics and Cervical Length. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 154-161.	1.4	93
224	Fetal Fraction in Maternal Plasma Cell-Free DNA at 11â€“13 Weeksâ€™ Gestation: Effect of Maternal and Fetal Factors. <i>Fetal Diagnosis and Therapy</i> , 2012, 31, 237-243.	1.4	132
225	Maternal serum ferritin at 11- to 13-week gestation in spontaneous early preterm delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1852-1855.	1.5	4
226	Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 692-698.	2.3	52
227	Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 699-705.	3.4	29
228	First-Trimester Prediction of Macrosomia. <i>Fetal Diagnosis and Therapy</i> , 2011, 29, 139-147.	1.4	57
229	Reference range of birth weight with gestation and firstâ€ trimester prediction of smallâ€ forâ€ gestation neonates. <i>Prenatal Diagnosis</i> , 2011, 31, 58-65.	2.3	100
230	Hypertensive Disorders in Pregnancy: Screening by Systolic Diastolic and Mean Arterial Pressure at 11â€“13 Weeks. <i>Hypertension in Pregnancy</i> , 2011, 30, 93-107.	1.1	68
231	Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11â€“13 weeks. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 35, 662-670.	1.7	142
232	Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPPâ€A at 11â€“13 weeks. <i>Prenatal Diagnosis</i> , 2010, 30, 216-223.	2.3	121
233	Normal Ranges of Embryonic Length, Embryonic Heart Rate, Gestational Sac Diameter and Yolk Sac Diameter at 6â€“10 Weeks. <i>Fetal Diagnosis and Therapy</i> , 2010, 28, 207-219.	1.4	76
234	Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. <i>Journal of Human Hypertension</i> , 2010, 24, 104-110.	2.2	265

#	ARTICLE	IF	CITATIONS
235	Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks. American Journal of Obstetrics and Gynecology, 2009, 200, 508.e1-508.e6.	1.3	27
236	First-Trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome. Prenatal Diagnosis, 2009, 29, 553-559.	2.3	52
237	First trimester urinary placental growth factor and development of pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 643-647.	2.3	27
238	First-Trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2009, 33, 135-141.	1.7	31
239	First-Trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2009, 33, 23-33.	1.7	196
240	Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound in Obstetrics and Gynecology, 2009, 33, 382-386.	1.7	40
241	Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks. Ultrasound in Obstetrics and Gynecology, 2009, 34, 142-148.	1.7	107
242	OC20.03: Hypertensive disorders in pregnancy: screening by uterine artery Doppler and blood pressure at 11-13 weeks. Ultrasound in Obstetrics and Gynecology, 2009, 34, 37-37.	1.7	0
243	Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound in Obstetrics and Gynecology, 2009, 34, 497-502.	1.7	106
244	First-Trimester Prediction of Hypertensive Disorders in Pregnancy. Hypertension, 2009, 53, 812-818.	2.7	389
245	Maternal serum placental growth factor (PIGF) in small for gestational age pregnancy at 11 <sup>+0</sup> to 13 <sup>+6</sup> weeks of gestation. Prenatal Diagnosis, 2008, 28, 1110-1115.	2.3	94
246	Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2008, 32, 138-146.	1.7	152
247	Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler and mean arterial pressure. Ultrasound in Obstetrics and Gynecology, 2008, 32, 877-883.	1.7	105
248	Cervical length and maternal factors in expectantly managed prolonged pregnancy: prediction of onset of labor and mode of delivery. Ultrasound in Obstetrics and Gynecology, 2008, 32, 646-651.	1.7	40
249	Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound in Obstetrics and Gynecology, 2008, 32, 732-739.	1.7	222
250	Urine albumin concentration and albumin-to-creatinine ratio at 11 <sup>+0</sup> to 13 <sup>+6</sup> weeks in the prediction of pre-eclampsia. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 866-873.	2.3	30
251	Inter-arm blood pressure differences in pregnant women. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 1122-1130.	2.3	29
252	First-Trimester Maternal Serum a Disintegrin and Metalloprotease 12 (ADAM12) and Adverse Pregnancy Outcome. Obstetrics and Gynecology, 2008, 112, 1082-1090.	2.4	62

#	ARTICLE	IF	CITATIONS
253	Mean Arterial Pressure at 11 <sup>+0</sup> to 13 <sup>+6</sup> Weeks in the Prediction of Preeclampsia. Hypertension, 2008, 51, 1027-1033.	2.7	104
254	Blood pressure levels correlate with intra-individual variability using an automated device in early pregnancy. Journal of Human Hypertension, 2008, 22, 438-440.	2.2	3
255	Audit of the effectiveness of cervical preparation with Dilapan prior to late second-trimester (20-24) Tj ETQq1 1 0.784314 rgBT /Overl Gynaecology, 2007, 114, 485-488.	2.3	17
256	Tetralogy of Fallot in the fetus in the current era. Ultrasound in Obstetrics and Gynecology, 2007, 29, 625-627.	1.7	62
257	OP04.10: Tetralogy of Fallot in the fetus in the current era. Ultrasound in Obstetrics and Gynecology, 2006, 28, 441-441.	1.7	0